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We aimed to link DNA methylation events occurring in cervical carcinomas to distinct stages of HPV-induced transformation.
Methylation specific-multiplex ligation-dependent probe amplification (MS-MLPA) analysis of cervical carcinomas revealed promoter
methylation of 12 out of 29 tumour suppressor genes analysed, with MGMT being most frequently methylated (92%). Subsequently,
consecutive stages of HPV16/18-transfected keratinocytes (n¼11), ranging from pre-immortal to anchorage-independent
phenotypes, were analysed by MS-MLPA. Whereas no methylation was evident in pre-immortal cells, progression to anchorage
independence was associated with an accumulation of frequent methylation events involving five genes, all of which were also
methylated in cervical carcinomas. TP73 and ESR1 methylation became manifest in early immortal cells followed by RARb and DAPK1
methylation in late immortal passages. Complementary methylation of MGMT was related to anchorage independence. Analysis of
nine cervical cancer cell lines, representing the tumorigenic phenotype, revealed in addition to these five genes frequent methylation
of CADM1, CDH13 and CHFR. In conclusion, eight recurrent methylation events in cervical carcinomas could be assigned to different
stages of HPV-induced transformation. Hence, our in vitro model system provides a valuable tool to further functionally address the
epigenetic alterations that are common in cervical carcinomas.
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Worldwide carcinoma of the uterine cervix is a leading cause of
cancer-related death for women (Pisani et al, 2002). The majority
of cervical carcinomas are squamous cell carcinomas (SCCs),
whereas adenocarcinomas (AdCAs) account for the remaining
15–20% of cases (Fu and Reagan, 1989; Pisani et al, 2002).
Development of cervical cancer is causally related to infection
with high-risk human papillomaviruses (hrHPVs), predominantly
types 16 and 18 (zur Hausen, 2002; Munoz et al, 2003). Although
hrHPVs can be detected in virtually all cervical SCCs and AdCAs
(Walboomers et al, 1999; Zielinski et al, 2003; Castellsague et al,
2006), progression of an hrHPV-positive premalignant lesion to
invasive cancer is a rare event. Consistent with the multistep
nature of human carcinogenesis, additive host cell alterations drive
progression to invasive cancer (Snijders et al, 2006). Insight in
these additional events may provide novel biomarkers for risk
assessment of hrHPV-infected women. These events may involve
chromosomal alterations affecting structure and expression of
(candidate) oncogenes and tumour suppressor genes, as well as
epigenetic alterations. The latter, including both histone modifica-
tions and DNA methylation, provide one mode of tumour
suppressor gene silencing (Esteller and Herman, 2002). DNA
methylation generally refers to the addition of a methyl group to
the 50 position of a cytosine base preceding a guanine. Methylation
of CpG-rich sequences, so-called CpG islands, which are often
present in gene promoter sequences, usually inhibits gene
transcription.
Molecular markers based on DNA methylation, that is methyla-
tion markers, are of particular interest as recent studies indicate
that DNA methylation can be easily detected in cervical scrapes
using sensitive PCR-based methods like methylation-specific
PCR (MSP). Moreover, positive MSP results in cervical scrapes
represented methylation of respective genes in the underlying
epithelium (Reesink-Peters et al, 2004; Feng et al, 2005).
To date, a number of studies have described aberrant
methylation of established or candidate tumour suppressor genes
in cervical carcinoma tissues, which include genes involved in
apoptosis, WNT signalling, Ras-signalling and tumour invasion
and metastasis (reviewed by Duenas-Gonzalez et al, 2005). In
several of these studies, methylation of up to 16 gene promoters
has been tested on cervical cancer biopsies, showing that up to
93% of them were positive for at least one of the methylation
markers tested (Dong et al, 2001; Virmani et al, 2001; Narayan
et al, 2003; Gustafson et al, 2004; Widschwendter et al, 2004; Feng
et al, 2005; Zambrano et al, 2005; Wisman et al, 2006). However,
for most of the genes studied, it is still unclear to what extent and
at what stage promoter methylation reflects a functionally
important step in the transformation process. This information
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swill greatly contribute to the design of a clinically optimal marker
panel for high-grade premalignant cervical lesions and cervical
cancer in terms of both sensitivity and specificity.
In order to decipher functionally important steps in HPV-
mediated transformation, a longitudinal in vitro model system of
hrHPV-transfected keratinocytes (Steenbergen et al, 1996) can,
next to cervical cancer cell lines, be of great value. We have
previously transfected primary human keratinocytes with full-
length HPV types 16 or 18, resulting in four immortal keratinocyte
cell lines, that is FK16A and FK16B containing HPV16, and FK18A
and FK18B containing HPV18 (Steenbergen et al, 1996). With
increasing passage, these cell lines revealed increasing severity of
dysplastic features in organotypic cultures that are reminiscent of
the various stages of premalignant cervical lesions (Steenbergen
et al, 1998b). Moreover, consecutive passages showed accumula-
tion of chromosomal alterations overlapping with those found in
cervical (pre)malignant lesions (Steenbergen et al, 1998a,b, 2005;
Wilting et al, 2006) and shared altered expression of certain genes
with these (pre)cancer stages (Steenbergen et al, 1996, 2002; van
Duin et al, 2003). It is currently, however, unknown to what extent
this system also provides a valuable model for studying epigenetic
alterations that are common in cervical carcinomas.
A novel method to assess the methylation status of multiple
genes is methylation specific multiplex ligation-dependent probe
amplification (MS-MLPA). MS-MLPA is a PCR-based technique
allowing the semiquantitative detection of changes in DNA
promoter methylation of multiple genes in a single reaction
(Nygren et al, 2005). Discrimination between methylated and
unmethylated targets is based on the annealing of probes
containing a recognition site for the methylation-sensitive restric-
tion enzyme HhaI.
In this study, we first assessed, by MS-MLPA, the genes out of
the 29 (candidate) tumour suppressor genes that are methylated in
cervical SCCs and AdCAs. Next, we determined at what stage
during HPV-mediated transformation methylation of identified
targets became manifest.
MATERIALS AND METHODS
Tissue specimens, cell lines and DNA isolation
Frozen specimens of 16 SCCs and eight AdCAs were collected
during the course of routine clinical practice at the VU University
Medical Center in Amsterdam. Serial cryosections were made, the
outer of which were used for histomorphological assessment.
All specimens included contained 470% tumour cells. The inner
sections were used for DNA extraction and HPV typing as
described previously (Wilting et al, 2006). This study followed the
ethical guidelines of the Institutional Review Board of the VU
University Medical Center.
Two primary keratinocyte cell lineages (EK05-1 and EK94-2)
were cultured using conditions described before (Steenbergen
et al, 1996). The cell lines FK16A, FK16B, FK18A and FK18B have
been established previously by transfection of primary foreskin
keratinocytes with either full-length HPV16 (FK16A and FK16B) or
HPV18 (FK18A and FK18B) (Steenbergen et al, 1996). The cells
were grown in serum-free keratinocyte growth medium (Life
Technologies, Breda, The Netherlands), supplemented with bovine
pituitary extract (50mgml
 1), epidermal growth factor (5ngml
 1),
penicillin (100Uml
 1), streptomycin (100mgml
 1) and L-glutamin
(2nM). Cells were harvested using 10mM trypsin (Life Technologies).
Anchorage-independent cell clones of FK16A and FK18B were
obtained by culturing late immortal cells in soft agarose, as
described previously (Steenbergen et al, 2004), resulting in the
outgrowth of a limited number of colonies. Of each cell line, a
single colony was isolated, referred to as FK16ASA and FK18BSA
and expanded further. Cervical cancer cell lines SiHa, HeLa and
CaSki were obtained from the American Type Tissue Culture
Collection (ATCC, Manassas, VA, USA). The six low passage
cervical cancer cell lines 778, 808, 866, 879 and 915 were kindly
provided by Professor Dr PL Stern and cultured as described
previously (Brady et al, 1999).
From cultured cells, DNA was isolated using the QIAmp tissue
kit (Qiagen, Hilden, Germany).
Methylation specific-multiplex ligation-dependent probe
amplification
The MS-MLPA was performed as published previously (Nygren
et al, 2005), using two probe mixtures (P041A and P041B). In total,
the probe mixtures contained a panel of probes specific for 29
candidate tumour suppressor genes (Table 1). Some of the genes
(i.e. APC, ATM, BRCA2, CHFR, CDH13, CDKN1B, CDKN2A,
CDKN2B, ESR1, FHIT, GSTP1, HIC1, MLH1, PTEN, RARb, RASSF1A,
STK11, TP73, CADM1 (previously referred to as TSLC1), VHL)
were represented by two or three probes that each recognised a
different Hha1 restriction site in the promoter region of the
respective genes. In addition, each probe mix contained control
probes that lack the Hha1 restriction site and were used for
quantification purposes.
The MS-MLPA procedure is summarised in Figure 1. For each
sample, 100ng input DNA was used. After 10min denaturation at
981C, SALSA MLPA buffer and MS-MLPA probe mix P041A or
P041B was added to the DNA, and the mixture was incubated for
1min at 951C, followed by hybridisation for 16h at 601C. After
hybridisation, the samples were diluted at room temperature with
H2O and 3ml ligase buffer A to a final volume of 20ml and divided
over two series of tubes. Samples were heated to 491C, after which
a volume of 10ml of a mix containing 0.25ml ligase, 1.5ml ligase
buffer B and 5U Hha1 (Promega, Leiden, The Netherlands) was
added. To the second series of tubes, an identical mix was added in
which Hha1 was replaced by 50% glycerol. Ligation and digestion
were performed simultaneously for 45min at 491C, which was
followed by a 5min incubation at 981C to inactivate the enzymes.
To amplify the ligation products, 5ml was added to a PCR mix
containing 10  SALSA PCR buffer, 1U SALSA polymerase and
SALSA FAM PCR primer-dNTP mix (all provided by MRC
Holland, Amsterdam, The Netherlands) and the following PCR
protocol was used: 1min at 951C; 35 cycles (30s at 951C, 30s at
601C, 1min at 721C); 20min at 721C.
For fragment analysis, 8.75ml Formamide (Sigma-Aldrich,
Zwijndrecht, The Netherlands), 0.25ml Gene Scan-500 ROX Size
Standard (PE Applied Biosystems, Foster City, CA, USA) and 1ml
PCR product was run on an ABI PRISM 3100 Avant (ABI PRISM
3100-Avant Genetic Analyzer by PE Applied Biosystems). Analysis
was performed using ABI 3100 Gene Scan 3.7 software. Each
amplified fragment was normalised by dividing the area under the
peak by the mean of the two flanking control fragments. The
percentage of methylation was calculated by dividing normalised
peaks in the Hha1-digested reaction by the normalised peaks in the
undigested control reaction. Methylation below the threshold level
of 10% was considered background (Nygren et al, 2005). All
samples were analysed twice and scored positive for methylation
when in both experiments the percentage of methylation for each
individual probe was above the threshold. In case of multiple
probes for a single gene promoter, the gene was scored positive
when X1 probe showed methylation.
Methylation-sensitive single-nucleotide primer extension
(Ms-SNuPE)
Primers used to generate the specific MGMT PCR product
for methylation-sensitive single-nucleotide primer extension
(Ms-SNuPE) analysis were 50-GTATTAGGAGGGGAGAGATT-30
and 50-TCTATACCTTAATTTACCAAATAACCC-30. The PCR was
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modified DNA. PCR conditions were 8min at 951C, 35 cycles (30s
at 951C, 30s at 541C, 45s at 721C); 4min at 721C. PCR products
were separated on 1% agarose gels and isolated using the
GeneClean III kit (Qbiogene, Irvine, CA, USA).
The Ms-SNuPE reactions were performed mainly as described
before with some modifications (Gonzalgo and Jones, 1997).
Conditions for primer extension reactions were: at 951C for 1min,
481C for 1min and 721C for 1min. The primers used for the
Ms-SNuPE analysis were 50-GGGATTTTTATTAAGCGGG-30 and
50-GGGATTTTTATTAAGTGGG-30.
The reaction was performed in a total volume of 10ml,
containing 4ml of purified PCR product and 6ml PCR mix
consisting of: 10  PCR buffer (MRC-Holland), 10pmol of each
Ms-SNuPE primer, 1mCi of either [
32P]dCTP or [
32P]dTTP and 1U
of Taq polymerase (MRC-Holland).
Stop solution was added and samples were denatured for 4min
at 951C. Of the sample, 1.5ml was loaded on a 15% polyacrylamide
gel (7 M urea).
Radioactivity was quantitated using a phosphoimager. The per-
centage of methylation is equivalent to the value of C/(CþT). The
specimens were rated positive when methylation level reached 5%.
Statistical analysis
Methylation percentages for individual genes in SCCs and AdCAs
were compared using w
2 statistical testing. A two-sided P-value of
p0.05 was considered significant.
RESULTS
Promoter methylation profiles in cervical SCCs and AdCAs
To firstly identify epigenetic alterations associated with cervical
cancer, we analysed promoter methylation of 29 (candidate)
tumour suppressor genes by MS-MLPA in 16 SCCs and eight
AdCAs. All carcinomas contained DNA of high-risk HPV types
(HPV16 in 10 SCCs and four AdCAs, HPV18 in one SCC and four
AdCAs, HPV33, 35 and 39 each in one SCC) or not yet classified
HPV types (HPV67 and 69, each in one SCC). An overview of all
genes that were methylated in the individual SCCs and AdCAs is
shown in Figure 2. In addition, a summary of the overall
frequencies of methylation found in SCCs and AdCAs is detailed
in Table 2. Twelve of the genes showed a positive MS-MLPA result
in one or more of the carcinomas tested. Squamous cell
carcinomas revealed frequent promoter methylation, that is in
440% of cases, of CDH13 (nine out of 16: 56.3%), DAPK1 (nine
out of 16: 56.3%), MGMT (15 out of 16: 93.8%) and CADM1 (nine
out of 16: 56.3%). In AdCAs, frequent promoter methylation of
APC (four out of eight: 50%), CDH13 (seven out of eight: 87.5%),
CHFR (four out of eight: 50%), MGMT (seven out of eight: 87.5%),
TIMP3 (five out of eight: 62.5%) and TP73 (seven out of eight:
87.5%) was detected.
MGMT was most frequently methylated in both tumour
histotypes, that is in 92% of all carcinomas. On the other hand,
methylation of DAPK1 (P¼0.007) and CADM1 (P¼0.04) was
significantly higher in SCCs, whereas APC (P¼0.01), CDKN2B
(P¼0.04), RASSF1A (P¼0.05), TIMP3 (P¼0.01) and TP73
(P¼0.02) methylation was more common in AdCAs (Table 2).
No statistically significant different methylation profiles were
found between HPV16-positive carcinomas and carcinomas
containing other hrHPV types.
Accumulation of methylation events during HPV-mediated
transformation in vitro
To determine at which stage during HPV-mediated transformation
methylation of the various genes becomes manifest, we performed
MS-MLPA analysis on an in vitro model system of HPV-
transformed keratinocytes and cervical cancer cell lines. In
previous studies, we and others have shown that at least four
phenotypes can be distinguished during HPV-mediated transfor-
Table 1 Genes represented by the probe mixtures (41A and 41B)
41A 41B
TIMP3 Tissue inhibitor of metalloproteinases-3 BRCA1 Breast cancer 1
APC Adenomatosis polyposis coli BRCA2 Breast cancer 2
CDKN2A Cyclin-dependent kinase inhibitor 2A; p16 ATM Ataxia telangiectasia mutated
MLH1 mutL homologue 1 TP53 Tumour protein 53
ATM Ataxia telangiectasia mutated PTEN Phosphatase and tensin homologue deleted on chromosome 10
RARB Retinoic acid receptor, beta SMARCA3 SWI/SNF-related, matrix-associated, actin-dependent regulator
of chromatin, subfamily a3
CDKN2B Cyclin-dependent kinase inhibitor 2B; p15 CHFR Checkpoint with forkhead and ring finger domains
HIC1 Hypermethylated in cancer 1 CDH13 Cadherin 13
CHFR Checkpoint with forkhead and ring finger domains TP73 Tumour protein p73
CASP8 Caspase 8 STK11 Serine/threonine kinase 11
CDKN1B Cyclin-dependent kinase inhibitor 1B; p27 VHL von Hippel–Lindau
PTEN Phosphatase and tensin homologue deleted on
chromosome 10
GSTP1 Glutathione S-transferase pi
BRCA2 Breast cancer 2 HIC1 Hypermethylated in cancer 1
CD44 CD44 molecule ESR1 Estrogen receptor 1
RASSF1A RAS association domain family 1A RB1 Retinoblastoma 1
DAPK1 Death-associated protein kinase 1 FHIT Fragile histidine triad gene
VHL von Hippel–Lindau STK11 Serine/threonine kinase 11
ESR1 Estrogen receptor 1 CADM1 Cell adhesion molecule 1
RASSF1A RAS association domain family 1A MGMT O6-methylguanine-DNA methyltransferase
TP73 Tumour protein p73 CDKN1B Cyclin-dependent kinase inhibitor 1B; p27
FHIT Fragile histidine triad gene APC Adenomatosis polyposis coli
CADM1 Cell adhesion molecule 1 CDKN2B Cyclin-dependent kinase inhibitor 2B; p15
CDH13 Cadherin 13 CDKN2A Cyclin-dependent kinase inhibitor 2A; p16
GSTP1 Glutathione S-transferase pi RASSF1A RAS association domain family 1A
MLH1 MutL homologue 1 RARB Retinoic acid receptor, beta
Probes present in both probe mixtures representing the same gene recognise a different restriction site in corresponding promoter regions.
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smation: (1) extended but still finite lifespan (pre-immortal), (2)
immortalisation (3) anchorage-independent growth and (4)
tumorigenicity (Chen et al, 1993; Steenbergen et al, 1996, 2005).
We analysed two isolates of primary keratinocytes as normal
controls and one HPV18-transfected cell culture (FK18B) repre-
senting the pre-immortal stage. Moreover, early passages (passage
39–61) and late passages (passage 75–124) of two HPV16 and two
HPV18 immortalised cell lines (FK16A, FK16B, FK18A and FK18B)
were included, as well as anchorage-independent clones of HPV16
(FK16ASA)- and HPV18 (FK18BSA)-containing cell lines. Finally,
nine hrHPV-positive cervical cancer cell lines (SiHa, HeLa, CaSki,
778, 808, 866, 873, 879 and 915), of which the latter six were tested
at low passage, were included as representatives of the tumorigenic
stage. A schematic representation of the cell lines analysed is
shown in Figure 3.
None of the 29 candidate tumour suppressor genes showed
promoter methylation in two cultures of primary keratinocytes,
nor in the pre-immortal passage of the cell line FK18B (Figure 4).
At the early immortal stage, promoter methylation of TP73 was
evident in all four cell lines and methylation of ESR1 in FK16A,
FK16B and FK18B cell lines. Additive methylation of RARb and
DAPK1 became apparent at later immortal passages of all cell lines.
Supplementary methylation of MGMT was associated with
anchorage-independent growth of FK16A and FK18B. Cervical
carcinoma cell lines, showed next to markers present in FK cell
lines, also revealed frequent methylation of CADM1 and CHFR.
In Figure 4A an overview of the MS-MLPA results on all cell
lines is shown. In Figure 4B, all genes that were found to be
methylated in more than 50% of all hrHPV-transformed cell lines
at the various stages of progression and in cervical carcinoma cell
lines are summarised. Notably, all eight genes that were frequently
methylated in the HPV-transfected cell lines and cervical cancer
cell lines (i.e. TP73, ESR1, RARb, DAPK1, MGMT, CADM1, CDH13
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Figure 2 Summary of MS-MLPA results on cervical SCCs (n¼16) and AdCAs (n¼8). Dark boxes indicate the presence of promoter methylation; light
boxes represent unmethylated CpGs. For each SCC and AdCA, the HPV type present is also shown.
Table 2 Methylation frequencies in SCCs and AdCAs
Gene SCC AdCa P-value
APC 6.3% (1/16) 50% (4/3) 0.01
CADM1 56.3% (9/16) 6.25% (1/8) 0.04
CDH13 56.3% (9/16) 87.5% (7/8) 0.13
CDKN2B 0% (0/0) 25% (2/0) 0.04
CHFR 31.3% (5/16) 50% (4/0) 0.37
DAPK1 56.3% (9/16) 0% (0/0) 0.01
ESR1 37.5% (0/16) 12.5% (1/8) 0.20
MGMT 93.8%(15/16) 87.5% (7/8) 0.60
RARb 12.5% (2/16) 12.5% (1/8) 1.00
RASSF1A 6.3% (1/16) 37.5% (3/0) 0.05
TIMP3 12.5% (2/16) 62.5% (5/0) 0.01
TP73 31.3% (5/16) 87.5% (7/0) 0.01
Genes indicated in bold italics are significantly more frequently methylated in AdCAs
than SCCs, and those in bold show a significantly higher frequency of methylation in
SCCs.
M
M
M
M
Methylated target 1 Unmethylated target 2
Denaturation and multiplex
probe hybridisation
Simultaneous ligation and digestion with
methylation-sensitive endonucleases
PCR with universal primers X and Y
Target 1
1A 1B
Target 2
2A 2B
Only ligated probes are
exponentially amplified
XY
5′ 3′
Fragment analysis
Figure 1 Overview of the MS-MLPA procedure (Nygren et al, 2005).
The gene-specific probes spanning a recognition site for the restriction
enzyme Hha1 are hybridised to the target DNA and subsequently ligated
and digested with the methylation-sensitive enzyme Hha1. Undigested
probes, that is probes of which the recognition sequence is methylated, will
be amplified. If the CpG site is unmethylated, the DNA/probe complex will
be digested and no amplification will take place. For each DNA sample, the
MS-MLPA was performed with and without Hha1 digestion.
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Figure 3 Schematic representation of the multistep process of HPV-mediated transformation in vitro, aligned with the hrHPV-transformed keratinocytes
and cervical cancer cell lines used in this study.
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Figure 4 (A) Summary of MS-MLPA results on primary keratinocytes (EK), HPV-transformed cell lines (FK16A, FK16B, FK18A, FK18B; p¼passage
number) and cervical carcinoma cell lines (CaSki, SiHa, HeLa, 778, 808, 866, 873, 879, 915). Only genes (20 out of 29) that were found to be
hypermethylated in at least one of the cell lines are shown. HPV types are listed for each cell line. (B) Longitudinal scheme of epigenetic events associated
with hrHPV-mediated transformation as detected in 450% of hrHPV-transformed cell lines and cervical carcinoma cell lines. *DAPK1 and CDH13
methylation was detected in 33% of carcinoma cell lines. Dark boxes indicate methylation positive, light boxes indicate methylation negative.
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cervical carcinoma specimens.
Confirmation of MS-MPLA results on MGMT promoter by
Ms-SNuPE
To confirm MS-MLPA results, we selected the MGMT gene for
further analysis, since this gene revealed the highest frequency of
positive MS-MLPA test results in cervical carcinoma specimens.
For this purpose, we used Ms-SNuPE analysis, by which
methylation differences at specific CpG sites can be assessed in a
quantitative manner (Gonzalgo and Jones, 1997). In this method,
DNA is treated with sodium bisulphite followed by amplification of
the target sequence using primers specific for bisulphite-converted
DNA. The subsequent primer extension reaction utilises an
internal primer which anneals to the PCR product and terminates
immediately 50 of the cytosine to be assayed,
32P-labelled dCTP and
dTTP and Taq polymerase. This is followed by denaturing
polyacryalamide gel electrophoresis and phosphorimage analysis
to quantitate the ratio of C versus T. To confirm our MS-MLPA
results, primers were specifically designed to examine the same
CpG dinucleotide as analysed by MS-MLPA (nt  459 relative to
the transcription start site).
Methylation-sensitive single-nucleotide primer extension analy-
sis of all cell lines confirmed MS-MLPA results for MGMT in all
cases (Figure 5). Cell lines SiHa and CaSki were positive in both
settings while the remaining cell lines were negative for MGMT
promoter methylation. Also in cervical cancer specimens,
Ms-SNuPE results were highly comparable to MS-MLPA results
(Figure 5). In all except two of the cancer specimens, MGMT
promoter methylation revealed identical results by MS-MLPA and
Ms-SNuPE. The two exceptions were SCC 42 (MS-MLPA positive,
Ms-SNuPE negative) and SCC 36 (MS-MLPA negative, Ms-SNuPE
positive). It should, however, be noted that in both cases
percentages of methylation measured with either or both
techniques were near the cutoff levels of the assays.
DISCUSSION
Methylation specific-multiplex ligation-dependent probe amplifi-
cation analysis of 29 tumour suppressor genes potentially targeted
by methylation resulted in the identification of 12 methylated gene
promoters in cervical carcinomas, eight of which could subse-
quently be associated with consecutive stages of HPV-mediated
transformation in vitro.
The MGMT promoter was most frequently methylated (i.e. in
92% of carcinomas). Next to the common marker MGMT, also
histotype-specific markers could be identified. DAPK1 and CADM1
were significantly more frequently methylated in SCCs while
methylation of APC, CDKN2B, RASSF1A, TIMP3 and TP73 was
significantly more frequent in AdCAs.
The detection of distinct methylation profiles between SCCs and
AdCAs is in concordance with literature data, showing higher
frequencies of DAPK1 promoter methylation in SCCs compared
with AdCAs (Dong et al, 2001; Narayan et al, 2003; Yang et al,
2004; Kang et al, 2006) and increased rates of APC, RASSF1A and
TIMP3 promoter methylation in AdCAs compared with SCCs
(Dong et al, 2001; Narayan et al, 2003; Jeong et al, 2006; Kang et al,
2006; Wisman et al, 2006).
Based on the analysis of consecutive passages of HPV-
transfected keratinocytes, we could assign methylation of the
different gene promoters as detected in cervical carcinomas to
distinct stages of transformation. Moreover, we showed that
despite the recent finding that HPV18 E7 targets DNA methyl
transferase 1 (DNMT1) involved in de novo methylation (Burgers
et al, 2007), none of the 29 genes were found to be methylated in
the pre-immortal cells expressing hrHPV E6 and E7. Only
following immortalisation, an accumulation of methylated genes
was detected, suggesting that inactivation of these genes is
associated with a growth advantage of the hrHPV-containing
keratinocytes. To what extent these genes (except CADM1;
Steenbergen et al, 2004) are functionally involved in the different
steps during the transformation process remains to be determined.
Methylation of both the TP73 and ESR1 promoter followed by
RARb and DAPK1 promoter methylation were identified as rather
early events associated with immortalisation. The recent demon-
stration of an inverse relation between ESR1 protein expression
and the severity of the cervical lesion (Bekkers et al, 2005)
supports our observation of ESR1 promoter methylation being a
rather early event during cervical carcinogenesis.
MGMT promoter methylation appeared as an intermediate
event, which is in line with earlier studies showing MGMT
promoter methylation in 26% of invasive cancers and 29% of high-
grade CIN lesions, compared with only 3% of low-grade CIN
lesions (Virmani et al, 2001).
Methylation of CHFR, CDH13 and CADM1 was only observed in
cervical carcinomas and cervical carcinoma cell lines and can as
such be designated as relative late events. To the best of our
knowledge, this is the first study showing methylation of CHFR to
be associated with cervical carcinogenesis. CHFR promoter
methylation has, however, been described in other types of cancer,
such as breast (Tokunaga et al, 2006), gastric (Kang et al, 2004)
and colorectal cancer (Brandes et al, 2005).
The detection of CADM1 promoter methylation in cervical
cancer cell lines is in concordance with our previous study
showing reduced CADM1 mRNA expression associated with
promoter methylation in nearly all cervical cancer cell lines, and
not in HPV-immortalised cells (Steenbergen et al, 2004).
Validation of our MS-MLPA results by Ms-SNuPE analysis, an
alternative method to specifically assess methylation of a single
CpG dinucleotide, confirmed the presence of MGMT methylation
(at position  459 relative to the transcription start site), in 92% of
carcinomas. The frequency of MGMT methylation as detected by
both techniques was different from most previous studies on
cervical carcinomas, in which by MSP analysis MGMT methylation
frequencies varying from 6.7 to 38% have been reported (Dong
et al, 2001; Virmani et al, 2001; Yang et al, 2004; Lin et al, 2005).
Interestingly, application of the same MSP assay as described in
these previous studies, by which methylation at the region from
CT CT CT CT CT CT CT CT
E Ms-SnuPE
Ms-MLPA
SiHa HeLa CaSki SCC4 SCC6 SCC12 SCC15 SCC21
Figure 5 Representative Ms-SNuPE results for MGMT promoter methylation in a subset of cell lines and SCC specimens. Dark boxes indicate the sample
was methylated and light boxes indicate the samples was unmethylated. Methylation specific-multiplex ligation-dependent probe amplification results for the
same CpG dinucleotide in the MGMT promoter are depicted below for comparison.
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showed evidence for methylation in only 31% of our carcinomas
(data not shown). This apparent discrepancy may, at least in part,
be explained by heterogeneity of MGMT promoter methylation in
cervical carcinomas.
On the other hand, MSP analysis of the cell lines for DAPK1,
ESR1, RARb and CADM1 promoter methylation showed a 78–89%
concordance between the MS-MLPA and MSP results (data not
shown). The absence of complete concordance may be explained
by the fact that MS-MLPA is only based on a single CpG site
compared to on average 4–6 CpG sites in MSP assays. Moreover,
different CpG dinucleotides were targeted by MS-MLPA and MSP,
indicating that, similar to MGMT, in the few discrepant cases
heterogeneous methylation patterns may exist within the indivi-
dual gene promoters.
Taken together, the present data illustrate the significance of our
in vitro model. In our previous studies we already showed that
both morphologically and genetically, the HPV-transfected cell
lines closely resembled cervical (pre)malignant lesions (Steenbergen
et al, 1996, 1998a, 2002; van Duin et al, 2003). The current study
indicates that also with respect to DNA methylation, this model
system nicely mimics cervical carcinogenesis in vivo. Conse-
quently, it provides a valuable tool to analyse the functional
involvement of the identified genes in the respective phenotypical
alterations during HPV-induced transformation.
Next to future functional studies, the linkage of the different
methylation events to distinct stages of HPV-induced malignant
transformation provided first insight in the potential clinical
applications of these markers. Early and intermediate methylation
events may provide markers for better risk assessment of hrHPV-
positive women with (ab)normal cytology. On the other hand, late
methylation events or a combination of the various events may be
used at the time of diagnosis for cancer staging and grading or
selection and monitoring of therapy. Future clinical validation
studies, for which specific guidelines have been proposed by Pepe
et al (2001), on cervical (pre)malignant and cervical scrapes, will
ultimately reveal the diagnostic value of the different methylation
markers. It should be taken into account that the specificity and
sensitivity of the different markers may need to be determined for
individual target population as frequencies of promoter methyla-
tion can vary among different ethnic groups (Enokida et al, 2005;
Das et al, 2006).
Gene alterations previously detected in our in vitro model
system, such as GATA-3, hTERT, MGP and CADM1, were also
found in clinical samples (Steenbergen et al, 2001, 2002, 2004; de
Wilde et al, 2007). Therefore, we believe that the methylation
events identified in the in vitro model system provide potential
markers for cervical cancer detection as well, which is underlined
by their large overlap with methylated gene promoters found in
cervical carcinomas.
In conclusion, MS-MLPA has proven to be a powerful tool to
identify genes targeted by DNA methylation in cervical carcino-
mas. In addition, we were able to link promoter methylation of
eight of the 12 identified markers to distinct stages of HPV-
induced malignant transformation. This resulted in more insight
into the natural sequence of methylation events as well as novel
candidates for future functional and clinical marker validation
studies.
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